Apixaban
Back to searchMolecule Structure
Scientific Name
Apixaban
Description of the Drug
Apixaban is an anticoagulant used for the prophylaxis of stroke and systemic embolism in nonvalvular atrial fibrillation, and deep vein thrombosis(DVT) leading to pulmonary embolism(PE), including in patients after a hip or knee replacement surgery.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB06605
http://www.drugbank.ca/drugs/DB06605
Brand Name(s)
Eliquis
Company Owner(s)
Micro Labs Ltd, Accord Healthcare Inc, Mylan Pharmaceuticals Inc, Bristol Myers Squibb Co Pharmaceutical Research Institute, Bionpharma Inc, Indoco Remedies Ltd, Breckenridge Pharmaceutical Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Coagulation factor X | SINGLE PROTEIN | INHIBITOR | CHEMBL244 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL118023 | |
| PharmGKB | PA166163740 | |
| Human Metabolome Database | HMDB0248515 | |
| DrugBank | DB06605 | |
| PubChem: Thomson Pharma | 15178464 | |
| PubChem | 10182969 | |
| LINCS | LSM-45660 | |
| Nikkaji | J2.566.952E | |
| PDBe | GG2 | |
| BindingDB | 19023 | |
| EPA CompTox Dashboard | DTXSID80436500 | |
| DrugCentral | 4298 | |
| Brenda | 85842 | 3564 |
| ChemicalBook | CB51508586 | |
| Guide to Pharmacology | 6390 | |
| rxnorm | APIXABAN | ELIQUIS |
| PubChem: Drugs of the Future | 56310620 | |
| ChEBI | 72296 | |
| ZINC | ZINC000011677837 |
